Literature DB >> 15046561

New variants in the apolipoprotein AV gene in individuals with extreme triglyceride levels.

J A Hubácek1, V Adámková, R Ceska, R Poledne, A Horínek, M Vráblík.   

Abstract

Animal studies (on transgenic and knock-out mice) and human association analysis assessed the importance of APOAV gene for plasma triglyceride determination. New APOAV missense variants (Val153 --> Met and Cys185 --> Gly) have been detected recently. We have analyzed these variants in 83 unrelated patients with extreme lipid parameters (triglycerides of 20.4+/-2.8 mmol/l and total cholesterol of 10.4+/-3.7 mmol/l) and in a control population group consisting of 2,559 unrelated Caucasians. In patients, the frequency of the Met153 carriers was slightly but not significantly higher (9.64 % vs. 6.49 %) compared to the population sample. This suggested that Val153 Met polymorphism in the APOAV gene does not represent an important risk factor for developing the extreme levels of plasma triglycerides. We did not detect carriers of the Gly185 allele among patients or 420 healthy individuals. We suppose that this variant is probably not present in Caucasian populations

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15046561

Source DB:  PubMed          Journal:  Physiol Res        ISSN: 0862-8408            Impact factor:   1.881


  12 in total

Review 1.  Genetic determinants of plasma triglycerides.

Authors:  Christopher T Johansen; Sekar Kathiresan; Robert A Hegele
Journal:  J Lipid Res       Date:  2010-11-01       Impact factor: 5.922

2.  Stepwise positive association between APOA5 minor allele frequencies and increasing plasma triglyceride quartiles in random patients with hypertriglyceridemia of unclarified origin.

Authors:  Ferenc Hadarits; Péter Kisfali; Márton Mohás; Anita Maász; Katalin Sümegi; Melinda Szabó; Katalin Hetyésy; Andrea Valasek; Ingrid Janicsek; István Wittmann; Béla Melegh
Journal:  Pathol Oncol Res       Date:  2010-05-19       Impact factor: 3.201

3.  Apolipoprotein A5 polymorphisms in Turkish population: association with serum lipid profile and risk of ischemic stroke.

Authors:  Birsen Can Demirdöğen; Esra Şahin; Aysun Türkanoğlu Özçelik; Semai Bek; Şeref Demirkaya; Orhan Adali
Journal:  Mol Biol Rep       Date:  2012-10-13       Impact factor: 2.316

4.  Apolipoprotein A-V variant (T-1131>C) affects plasma levels of non-high-density lipoprotein cholesterol in Caucasians.

Authors:  Jaroslav A Hubacek; Zdena Skodová; Vera Lánská; Vera Adámková
Journal:  Exp Clin Cardiol       Date:  2008

5.  APOAV (T-1131>C) variant has no effect on mother's height in a large population study.

Authors:  Jaroslav A Hubacek; Zdena Skodova; Vera Adamkova; Vera Lanska; Dagmar Bobkova; Rudolf Poledne
Journal:  Lipids Health Dis       Date:  2004-05-24       Impact factor: 3.876

6.  Interactions of the apolipoprotein A5 gene polymorphisms and alcohol consumption on serum lipid levels.

Authors:  Rui-Xing Yin; Yi-Yang Li; Wan-Ying Liu; Lin Zhang; Jin-Zhen Wu
Journal:  PLoS One       Date:  2011-03-14       Impact factor: 3.240

7.  Apolipoprotein A1/C3/A5 haplotypes and serum lipid levels.

Authors:  Rui-Xing Yin; Yi-Yang Li; Chao-Qiang Lai
Journal:  Lipids Health Dis       Date:  2011-08-19       Impact factor: 3.876

8.  Haplotype analysis of the Apolipoprotein A5 gene in Moroccan patients with the metabolic syndrome.

Authors:  Maria Ajjemami; Sanaa Ouatou; Hicham Charoute; Malika Fakiri; Houria Rhaissi; Houda Benrahma; Hassan Rouba; Abdelhamid Barakat
Journal:  J Diabetes Metab Disord       Date:  2015-04-16

9.  Genetic Variants Associated with Gestational Hypertriglyceridemia and Pancreatitis.

Authors:  Sai-Li Xie; Tan-Zhou Chen; Xie-Lin Huang; Chao Chen; Rong Jin; Zhi-Ming Huang; Meng-Tao Zhou
Journal:  PLoS One       Date:  2015-06-16       Impact factor: 3.240

10.  DNA polymorphisms and haplotypes of apolipoprotein A5's attribution to the plasma triglyceride levels in Koreans.

Authors:  Jung Ran Choi; Chung Mo Nam; Dae Ryong Kang; Sang Mi Eom; Hye Jin Lee; Chan Mi Park; Jin Woo Im; Yangsoo Jang
Journal:  Yonsei Med J       Date:  2007-08-31       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.